Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
A young woman with curly hair smiles on a city street.

Sickle Cell Disease Treatments Compared

5 FDA-approved drugs, plus 2 in development, side by side from the current prescribing labels. Newest label Jul 2026. Checked November 3, 2026.

The full Sickle Cell Disease guide, with open trials and help paying →

One-time gene therapiesCasgevy · Lyfgenia
Daily oralDroxia (also Siklos) · Endari
Monthly infusionAdakveo

Five treatments are FDA-approved for sickle cell disease: 2 one-time gene therapies and 3 medicines taken on an ongoing basis.

  • Casgevy and Lyfgenia, both approved December 8, 2023, are given once in a transplant hospital after high-dose chemotherapy.
  • In their trials, 29 of 31 Casgevy patients had no severe pain crises for at least 12 months in a row. Among Lyfgenia patients, 28 of 32 had no vaso-occlusive events between months 6 and 18.
  • Hydroxyurea, a daily capsule or tablet approved for sickle cell in 1998, cut painful crises from 4.6 to 2.5 a year against placebo.
  • Adakveo is a monthly clinic infusion whose label now says its confirmatory trial did not establish benefit.
  • Endari is an oral powder twice a day that cut crises by about 25%.
  • Mitapivat, a twice-daily pill, now has an FDA decision date of February 1, 2027, after the FDA extended its review from November 1, 2026.

Latest for sickle cell disease

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

Free email alert

Email me the day the FDA decides on Mitapivat

You get one email when the decision is public, plus new trials and FDA news for this condition.

You'll get trial alerts and disease updates for Sickle Cell Disease, and you can turn either off anytime. We never share your email. Privacy policy

Side by side

5 approved sickle cell disease treatments at a glance

How each drug is given, how often, who it is approved for and when it was first approved, from the current FDA label.

Sickle Cell Disease treatments compared: route, schedule, approved use and approval date
DrugHow it is givenHow oftenApproved forFirst approved
exagamglogene autotemcel
Vertex Pharmaceuticals / CRISPR Therapeutics
One-time IV infusion of your own CRISPR-edited stem cells, given in a transplant hospital after high-dose busulfan chemotherapy; stem cells are collected weeks earlierone-timePeople 2 and older with sickle cell disease and recurrent vaso-occlusive crisesDecember 8, 2023
lovotibeglogene autotemcel
Genetix Biotherapeutics (formerly bluebird bio)
One-time IV infusion of your own gene-modified stem cells, given in a transplant hospital after high-dose busulfan chemotherapy; stem cells are collected weeks earlierAbout 30 minutes per doseone-timePeople 12 and older with sickle cell disease and a history of vaso-occlusive eventsDecember 8, 2023
hydroxyurea
Waylis Therapeutics (Droxia); Medunik (Siklos); generics also sold
Capsule (Droxia) or tablet (Siklos) by mouth once a dayOnce daily; start 15mg/kg (20mg/kg for children on Siklos), raise by 5mg/kg every 8 to 12 weeks to a max of 35mg/kg/day; blood counts every 2 weeksSickle cell anemia with recurrent moderate to severe painful crises; Siklos covers ages 2 and olderFebruary 25, 1998
crizanlizumab-tmca
Novartis
IV infusion at a clinic over 30 minutesAbout 30 minutes per dose5mg/kg at week 0 and week 2, then every 4 weeks; can be used with or without hydroxyureaAdults and children 16 and older with sickle cell disease, to reduce vaso-occlusive crisesNovember 15, 2019
L-glutamine oral powder
Emmaus Medical
Powder mixed into a drink or soft food, by mouth twice a day5g, 10g or 15g twice daily by body weight (1 to 3 packets per dose)Adults and children 5 and older with sickle cell disease, to reduce acute complicationsJuly 7, 2017
The calendar

A year on each sickle cell disease treatment

Every dose in a year, drawn to the label schedule, so you can see at a glance how often each one is given.

Casgevy
One-time gene therapy, at a clinic
Given once
Lyfgenia
One-time gene therapy, at a clinic
Given once
Droxia (also Siklos)
By mouth, at home
365 doses a year
Adakveo
Infusion, at a clinic
13 doses a year
Endari
Other, at home
730 doses a year

Counts follow the label schedule for a full year on the maintenance dose. Drugs given in cycles or adjusted to blood tests have no fixed count, so their schedule is written out instead.

The evidence

What the pivotal sickle cell disease trials showed

The primary result from the trial each FDA approval rests on, as reported on the label.

Sickle Cell Disease pivotal trial results by drug
DrugPivotal trialPrimary result
exagamglogene autotemcel
Vertex Pharmaceuticals / CRISPR Therapeutics
Trial 1 (NCT03745287), 44 treated aged 12 and older, 31 evaluable; plus Trial 4, 11 children aged 5 to 11
Trial record or paper
29 of 31 evaluable patients (93.5%) had no severe VOCs for at least 12 months in a row; all 8 evaluable children aged 5 to 11 did too
lovotibeglogene autotemcel
Genetix Biotherapeutics (formerly bluebird bio)
Study 1-C (NCT02140554), Phase 1/2, 36 treated, 32 evaluable for VOE outcomes
Trial record or paper
28 of 32 (88%) had no vaso-occlusive events between months 6 and 18 after infusion; 30 of 32 (94%) had no severe VOEs
hydroxyurea
Waylis Therapeutics (Droxia); Medunik (Siklos); generics also sold
MSH (Multicenter Study of Hydroxyurea in Sickle Cell Anemia), 299 adultsMedian 2.5 painful crises a year vs 4.6 on placebo (46% fewer); crises needing hospital care 1.0 vs 2.5 a year
crizanlizumab-tmca
Novartis
SUSTAIN (NCT01895361), 198 people; 67 on the approved dose vs 65 on placebo
Trial record or paper
Median 1.63 VOCs a year vs 2.98 on placebo (p=0.010); 36% had no VOC vs 17%
L-glutamine oral powder
Emmaus Medical
Phase 3 (NCT01179217), 230 people aged 5 to 58
Trial record or paper
Median 3 sickle cell crises over 48 weeks vs 4 on placebo; hospital stays for pain 2 vs 3; about 25% fewer crises overall (rate ratio 0.75)
Safety

Sickle Cell Disease treatment side effects and warnings

Lyfgenia and Droxia (also Siklos) carry a boxed warning, the FDA's strongest. The rest list their main precautions. Side effect rates show how many people in each drug's trials reported each one, whether or not the drug caused it.

Sickle Cell Disease treatments: most common side effects and key warnings from the FDA labels
DrugMost common side effectsKey warning
exagamglogene autotemcel
Vertex Pharmaceuticals / CRISPR Therapeutics
mouth sores (mucositis) 86%, fever with low white cells 48% and decreased appetite 41%No boxed warning. Engraftment failure, delayed platelet recovery with bleeding risk, allergic reactions, and possible off-target gene edits.
lovotibeglogene autotemcel
Genetix Biotherapeutics (formerly bluebird bio)
mouth sores (stomatitis) 71%, low platelets (clotting cells) 69% and low infection-fighting white cells 60%Boxed warning Boxed warning: blood cancer (hematologic malignancy) has occurred in treated patients; lifelong monitoring with blood counts at least every 6 months.
hydroxyurea
Waylis Therapeutics (Droxia); Medunik (Siklos); generics also sold
infections 43%, headache 20% and dry skin 12%Boxed warning Boxed warning: severe bone marrow suppression (low blood counts) and cancer risk; hydroxyurea is carcinogenic.
crizanlizumab-tmca
Novartis
joint pain 18%, nausea 18% and back pain 15%No boxed warning. Infusion-related reactions, some needing hospital care; interference with automated platelet counts.
L-glutamine oral powder
Emmaus Medical
constipation 21%, nausea 19% and headache 18%No boxed warning. The label has no Warnings and Precautions section.
Not yet approved

Sickle cell disease treatments in Phase 3 or under FDA review

Investigational drugs with a Phase 3 trial, shown separately because their results are not from a label. Status as of the date in each row.

Sickle Cell Disease drugs not FDA-approved
DrugStatusHow it works and is givenPivotal trialResult so farWhat is next
Agios Pharmaceuticals
Under FDA reviewas of November 3, 2026Oral pyruvate kinase activator that boosts red blood cell energy and lowers hemolysisPill by mouth twice a day (100mg)RISE UP, Phase 2/3 (NCT05031780); 207 people aged 16 and older in the Phase 3 part, 2:1 to mitapivat or placeboPrimary endpoint: Two primary endpoints: hemoglobin response (rise of at least 1g/dL, weeks 24 to 52) and annualized rate of sickle cell pain crises
ClinicalTrials.gov
Met hemoglobin response: 40.6% vs 2.9% on placebo (p<0.0001). Did not meet pain crises: 2.62 vs 3.05 a year (p=0.12). Fatigue endpoint also not met (Agios press release, 2025-11-19)FDA decision (PDUFA date) February 1, 2027, moved from November 1, 2026 after the FDA classified Agios's October 19 response on a possible REMS as a major amendment (Agios, 2026-10-30)
Agios press release, October 30, 2026 (new PDUFA date); Agios press release, Nov 19, 2025 (RISE UP topline results)
Novo Nordisk
Under FDA reviewas of November 15, 2026Oral pyruvate kinase activator that lowers 2,3-DPG and raises ATP in red blood cellsBy mouth once a day (400mg in HIBISCUS)HIBISCUS, Phase 2/3 (NCT04624659); 385 people aged 12 and older in the 52-week Phase 3 comparison with placeboPrimary endpoint: Two primary endpoints: hemoglobin response at week 24 and annualized rate of vaso-occlusive crises over 52 weeks
ClinicalTrials.gov
Met both: 27% lower crisis rate; hemoglobin response 48.7% vs 7.2%; median time to first crisis 38.4 vs 20.9 weeks (Novo Nordisk, 2026-04-20)NDA submitted to the FDA, announced November 13, 2026; Novo expects FDA action in 2027, with no acceptance or decision date announced
Novo Nordisk press release, November 13, 2026 (submission); Novo Nordisk, April 20, 2026 (HIBISCUS results)
Cost

Help paying for sickle cell disease treatment

Drugmaker copay and free-drug programs, plus charity funds for the condition, checked every week.

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read
Follow Sickle Cell Disease treatment news by email

One email when the FDA acts on a Sickle Cell Disease treatment, a label changes or a new trial opens. Never a newsletter.

You'll get, for Sickle Cell Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Questions

Sickle Cell Disease treatment questions people ask

What is the difference between Casgevy and Lyfgenia?

Both are one-time gene therapies made from your own stem cells and given after busulfan chemotherapy, approved the same day in December 2023. In their trials, 29 of 31 Casgevy patients (94%) had no severe crises for at least 12 consecutive months, and 28 of 32 Lyfgenia patients (88%) had no vaso-occlusive events between months 6 and 18. Lyfgenia carries a boxed warning for blood cancer; Casgevy does not. Casgevy is approved from age 2 and Lyfgenia from age 12.

Does hydroxyurea still work for sickle cell disease?

Yes. Hydroxyurea is the longest-used sickle cell drug, with placebo-controlled evidence on crisis rates: in the MSH trial, adults had a median 2.5 painful crises a year against 4.6 on placebo, and crises needing hospital care fell from 2.5 to 1.0 a year. It is sold as Droxia capsules, Siklos tablets for age 2 and up, and generics.

Is Adakveo still recommended?

Adakveo (crizanlizumab) remains FDA-approved, but its label, updated in June 2024, says the confirmatory STAND trial did not establish efficacy, with 2.49 crises a year on Adakveo against 2.30 on placebo, and tells doctors to reassess whether to continue it each year. Its original approval rested on SUSTAIN, where crises fell from 2.98 to 1.63 a year.

Is mitapivat approved for sickle cell disease?

Not as of November 3, 2026. Mitapivat is approved for other anemias, and Agios said on October 30, 2026 that the FDA moved its sickle cell decision date from November 1, 2026 to February 1, 2027. In its Phase 3 trial, 40.6% had a hemoglobin response against 2.9% on placebo, but the pain crisis endpoint was not met, 2.62 against 3.05 crises a year.

Go deeper

More on Sickle Cell Disease at Trial Friend

Sources

Where every number on this page comes from

Approved-drug facts are from the current FDA prescribing information on DailyMed or the FDA's own site, with the label's effective date. Investigational-drug facts are from ClinicalTrials.gov and the sources named in each row.

  1. Casgevy (exagamglogene autotemcel) prescribing information, Vertex Pharmaceuticals / CRISPR Therapeutics, label dated Jul 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  2. Lyfgenia (lovotibeglogene autotemcel) prescribing information, Genetix Biotherapeutics (formerly bluebird bio), label dated Jul 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  3. Droxia (also Siklos) (hydroxyurea) prescribing information, Waylis Therapeutics (Droxia); Medunik (Siklos); generics also sold, label dated Sep 2025. DailyMed
  4. Adakveo (crizanlizumab-tmca) prescribing information, Novartis, label dated Jun 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  5. Endari (L-glutamine oral powder) prescribing information, Emmaus Medical, label dated Jun 2025. DailyMed. Pivotal trial: ClinicalTrials.gov
  6. mitapivat (Pyrukynd / Aqvesme), Agios Pharmaceuticals: ClinicalTrials.gov record; Agios press release, October 30, 2026 (new PDUFA date); Agios press release, Nov 19, 2025 (RISE UP topline results). Checked November 3, 2026.
  7. etavopivat, Novo Nordisk: ClinicalTrials.gov record; Novo Nordisk press release, November 13, 2026 (submission); Novo Nordisk, April 20, 2026 (HIBISCUS results). Checked November 15, 2026.

This page compares what the FDA labels and pivotal trials report. It is not medical advice, and no trial on this page compared these drugs with each other. Written and checked by Jason Hunter; the method is on the editorial standards page.